A phase II trial to assess the efficacy, safety and feasibility of 20[percnt] subcutaneous immunoglobulin in patients with myasthenia gravis exacerbation-interim analysis of safety and feasibility

Authors
Category Primary study
JournalNeurology
Year 2016
This article has no abstract
Epistemonikos ID: 5facdac209c7f2fdc8ec1eaf3c63e5ada34a6a91
First added on: Feb 07, 2025